Jolanda M. van Dieren

Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial

Y.L. Verschoor, Joris van de Haar, José G. van den Berg et al. · Nature Medicine · 2024 · 107 citations · Full text

Medicine, Oncology, Pharmacology +17

Contributions of mucosal immune cells to methotrexate-induced mucositis

Barbara AE de Koning, Jolanda M. van Dieren, Dicky J. Lindenbergh-Kortleve et al. · International Immunology · 2006 · 92 citations · Full text

Life Sciences, Immunology, Pathology +17

Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial

Berend J. van der Wilk, Ben M. Eyck, Bas P. L. Wijnhoven et al. · The Lancet Oncology · 2025 · 90 citations · Full text

Medicine, Oncology, Surgery +17

Local application of tacrolimus in distal colitis: Feasible and safe

Jolanda M. van Dieren, Ad A. van Bodegraven, Ernst J. Kuipers et al. · Inflammatory Bowel Diseases · 2008 · 85 citations

Pharmacy, Clinical Pharmacokinetics, Immunology +17

A population-based study on intestinal and diffuse type adenocarcinoma of the oesophagus and stomach in the Netherlands between 1989 and 2015

Rosa T. van der Kaaij, Willem J. Koemans, Margreet van Putten et al. · European Journal of Cancer · 2020 · 68 citations

Medicine, Oncology, Surgery +14